Allison L Agwu1, John A Fleishman2, Richard Rutstein3, P Todd Korthuis4, Kelly Gebo5. 1. Division of Pediatric Infectious Diseases, Department of Pediatrics, and Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, and ageorg10@jhmi.edu. 2. Center for Financing, Access, and Cost Trends, Agency for Health Care Research and Quality, Rockville, Maryland. 3. Division of General Pediatrics, Children's Hospital of Philadelphia, Pennsylvania; and Departments of. 4. Internal Medicine Public Health and Preventive Medicine, Oregon Health and Science University, Portland. 5. Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, and.
Abstract
BACKGROUND: Due to successful antiretroviral therapy (ART), perinatally human immunodeficiency virus (PHIV)-infected children are reaching adolescence and young adulthood. Adolescence is characterized by factors (eg, increased risk-taking) that may hamper management. We examined PHIV-infected youth in a multisite US cohort, assessing factors associated with changes in advanced immunosuppression and detectable viremia over time. METHODS: We conducted a retrospective study of 521 PHIV-infected youth, 12 years and older, followed at 16 HIV clinics in the HIV Research Network between 2002 and 2010. We assessed demographic and clinical factors associated with CD4 <200 cells/mm(3) and viral load ≥2.60 log10 HIV-1 RNA copies/mL using multivariable logistic regression. RESULTS: Between 2002 and 2010, the median age of PHIV-infected youth in care increased from 14 to 18 years. The proportion prescribed ART increased from 67.4% to 84%, with virologic suppression increasing from 35.5% to 63.0% (P trend < .01). Older age, Black and Hispanic race/ethnicity, and increasing viremia were independently associated with CD4 <200 cells/mm(3). Older age, Black race and Hispanic ethnicity were independently associated with higher likelihood of detectable viremia, whereas more recent year of evaluation and being prescribed ART were associated with a lower likelihood. CONCLUSIONS: The proportion of PHIV-infected youth on ART has increased. Rates of viremia and advanced immunosuppression have decreased in recent years, but both rates are higher for older PHIV-infected youth. Factors associated with advanced immunosuppression and viremia offer the chance to define strategies to optimize outcomes.
BACKGROUND: Due to successful antiretroviral therapy (ART), perinatally human immunodeficiency virus (PHIV)-infectedchildren are reaching adolescence and young adulthood. Adolescence is characterized by factors (eg, increased risk-taking) that may hamper management. We examined PHIV-infected youth in a multisite US cohort, assessing factors associated with changes in advanced immunosuppression and detectable viremia over time. METHODS: We conducted a retrospective study of 521 PHIV-infected youth, 12 years and older, followed at 16 HIV clinics in the HIV Research Network between 2002 and 2010. We assessed demographic and clinical factors associated with CD4 <200 cells/mm(3) and viral load ≥2.60 log10 HIV-1 RNA copies/mL using multivariable logistic regression. RESULTS: Between 2002 and 2010, the median age of PHIV-infected youth in care increased from 14 to 18 years. The proportion prescribed ART increased from 67.4% to 84%, with virologic suppression increasing from 35.5% to 63.0% (P trend < .01). Older age, Black and Hispanic race/ethnicity, and increasing viremia were independently associated with CD4 <200 cells/mm(3). Older age, Black race and Hispanic ethnicity were independently associated with higher likelihood of detectable viremia, whereas more recent year of evaluation and being prescribed ART were associated with a lower likelihood. CONCLUSIONS: The proportion of PHIV-infected youth on ART has increased. Rates of viremia and advanced immunosuppression have decreased in recent years, but both rates are higher for older PHIV-infected youth. Factors associated with advanced immunosuppression and viremia offer the chance to define strategies to optimize outcomes.
Authors: Anne M Neilan; Brad Karalius; Kunjal Patel; Russell B Van Dyke; Mark J Abzug; Allison L Agwu; Paige L Williams; Murli Purswani; Deborah Kacanek; James M Oleske; Sandra K Burchett; Andrew Wiznia; Miriam Chernoff; George R Seage; Andrea L Ciaranello Journal: JAMA Pediatr Date: 2017-05-01 Impact factor: 16.193
Authors: Christina M Meade; Sophia A Hussen; Florence Momplaisir; Martina Badell; Stephanie Hackett; Anandi N Sheth Journal: AIDS Care Date: 2017-12-18
Authors: Shoshana Y Kahana; Maria Isabel Fernandez; Patrick A Wilson; Jose A Bauermeister; Sonia Lee; Craig M Wilson; Lisa B Hightow-Weidman Journal: J Acquir Immune Defic Syndr Date: 2015-02-01 Impact factor: 3.731
Authors: Deborah Kacanek; Yanling Huo; Kathleen Malee; Claude A Mellins; Renee Smith; Patricia A Garvie; Katherine Tassiopoulos; Sonia Lee; Claire A Berman; Mary Paul; Ana Puga; Susannah Allison Journal: AIDS Date: 2019-10-01 Impact factor: 4.177
Authors: Allison L Agwu; Jennifer Y Chang; Ryan E Wiegand; John T Wheeling; Beverly A Bohannon; Kenneth L Dominguez Journal: AIDS Patient Care STDS Date: 2014-01 Impact factor: 5.078
Authors: Stephen A Berry; Kelly A Gebo; Richard M Rutstein; Keri N Althoff; P Todd Korthuis; Aditya H Gaur; Stephen A Spector; Robert Warford; Baligh R Yehia; Allison L Agwu Journal: Pediatr Infect Dis J Date: 2014-05 Impact factor: 2.129
Authors: Allison L Agwu; Tzy-Jyun Yao; Susan H Eshleman; Kunjal Patel; Wei Huang; Sandra K Burchett; George K Siberry; Russell B Van Dyke Journal: Pediatr Infect Dis J Date: 2016-07 Impact factor: 2.129